Breaking News, Collaborations & Alliances

BMS, AZ Enter Worldwide Diabetes Collaboration

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Bristol-Myers Squibb and AstraZeneca entered into a collaboration to develop and commercialize two investigational compounds discovered by BMS for the treatment of Type 2 diabetes. Saxagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, is currently in Phase III development. Pending successful completion of the program, the companies plan to file for U.S. regulatory approval during the first half of 2008. Dapagliflozin, a sodium-glucose cotransporter-2 (SGLT2) inhibitor, is currently in ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters